-
Views
-
Cite
Cite
Hui Juan Zhu, Hui Pan, Yan Cui, Xiang Qing Wang, Lin Jie Wang, Nai Shi Li, Hong Bo Yang, Feng Ying Gong, The Changes of Serum Glypican4 in Obese Patients With Different Glucose Metabolism Status, The Journal of Clinical Endocrinology & Metabolism, Volume 99, Issue 12, December 2014, Pages E2697–E2701, https://doi.org/10.1210/jc.2014-2018
Close - Share Icon Share
Glypican 4 (Gpc4) was identified as a novel adipokine capable of intensifying insulin signaling and regulating adipocyte differentiation. This study was performed to investigate the changes of serum Gpc4 levels in obese patients with different glucose metabolism status and its association with metabolic-related parameters.
A total of 170 obese patients with different glucose metabolism status and 38 normal controls were recruited, and obese patients were divided into 4 groups: OB1, obese patients with normal glucose tolerance (NGT) and normal insulin levels; OB2, obese patients with normal glucose tolerance and hyperinsulinemia; OB3, obese patients with impaired glucose tolerance; and OB4, obese patients with type 2 diabetes mellitus. Serum Gpc4 was determined by commercially available ELISA kits.
Serum Gpc4 levels in the OB2, -3, and -4 groups were significantly increased in comparison with that in the OB1 group (3.5 [2.0–5.3] ng/mL, 3.0 [1.5–6.1] ng/mL, and 3.4 [1.8–5.4] ng/mL vs 1.9 [1.3–4.3] ng/mL, P < .05). The levels were positively correlated with body mass index (BMI), systolic blood pressure (SBP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting insulin (FINS), and homeostasis model assessment of insulin resistance (HOMA-IR) in all subjects. Multiple linear regression showed that SBP, AST, HOMA-IR, and FINS were independent contributors to circulating Gpc4 levels after adjusting for age, gender, and BMI in all subjects (P < .05). Additionally, serum Gpc4 levels in males of the normal group and the OB3 group were higher than those in females (2.9 [2.1–4.9] ng/mL vs 1.6 [1.2–3.1] ng/mL; 4.8 [2.5–6.3] ng/mL vs 2.7 [1.1–4.4] ng/mL, P < .05).
Serum Gpc4 levels were significantly elevated in obese patients with insulin resistance and positively correlated with BMI, SBP, ALT, AST, FINS, and HOMA-IR, suggesting Gpc4 is a novel adipokine associated with obesity and insulin resistance-related metabolic disorders.
